Andrew Huberman· PhD
And you have muscarinic receptors and nicotinic receptors, and there's just better ways to optimize your nicotinic receptor activity. For example, acetylcholine precursors like alpha GPC, phosphatidylserine, phosphatidylcholine.
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
And you have muscarinic receptors and nicotinic receptors, and there's just better ways to optimize your nicotinic receptor activity. For example, acetylcholine precursors like alpha GPC, phosphatidylserine, phosphatidylcholine.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Alpha GPC.